Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Nilotinib can cause keratosis pilaris, a skin condition.

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Keratinocytes can reverse the effects of the GNAQ oncogene, inhibiting melanoma cell growth.

Abrocitinib may effectively treat stubborn alopecia universalis.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Cepharanthine can potentially treat gastric cancer by stopping tumor growth.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.

Upadacitinib may effectively treat alopecia areata without side effects.

Pulsed electric field treatment may help shrink untreated liver tumors.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.